ABSTRACT
We review the available published data on the effect of LE on IOP and report on the cumulative incidence of clinically significant IOP elevations (C10 mm Hg from baseline) with short-term and long-term LE use. In all studies, LE consistently demonstrated a low propensity to elevate IOP, regardless of formulation, dosage regimen, or treatment duration, including in known steroid responders. The cumulative proportion of patients exhibiting clinically significant IOP increases was 0.8% (14/1725 subjects) in studies evaluating short-term LE treatment and 1.5% (21/1386 subjects) in
INTRODUCTION
Topical corticosteroids are widely used to treat inflammatory conditions of the ocular surface and the anterior segment. Acting through the cytosolic glucocorticoid receptors and exerting their effects predominantly at the genomic level, corticosteroids possess broad mechanisms of action and potent anti-inflammatory activity [1] [2] [3] . By inhibiting upstream phospholipase A2, they block both the cyclooxygenase and lipoxygenase pathways of the inflammatory cascade and thus prevent formation of all eicosanoids [2, 3] . In addition, they are known to inhibit inflammatory cytokines, chemokines, adhesion molecules, and other inflammatory mediators [1, 4] .
These pathways are involved in the progression of many ocular surface and anterior segment inflammatory conditions, including post-surgical inflammation, anterior uveitis, blepharitis, and dry eye. Additionally, corticosteroids reduce synthesis of histamine, stabilize cell membranes, and inhibit degranulation of mast cells, making topical corticosteroids an effective treatment for ocular allergic inflammatory conditions [5, 6] .
In addition to their therapeutic effects, corticosteroids can produce a number of adverse side effects, including cataract formation, increased susceptibility to microbial infection, delayed wound healing, and, the focus of this review, intraocular pressure (IOP) elevation [7, 8] . Corticosteroid-induced ocular hypertension may occur with any mode of administration, but is much more common with topical corticosteroids than with corticosteroid systemic therapies [9] [10] [11] .
Besides the active moiety itself, factors contributing to the IOP-raising potential of a specific topical corticosteroid include ocular pharmacokinetics, dosage, and treatment duration [7, 12] . IOP elevation has been found to be common with older corticosteroids such as dexamethasone and prednisolone [12, 13] . Difluprednate, one of the newer corticosteroids and a difluorinated derivative of prednisolone, also demonstrates a higher propensity to raise IOP in comparison to corticosteroids such as LE and rimexolone [12] . It has long been recognized that, in the general adult population, about one-third will experience IOP elevations of 6-15 mm Hg (moderate responders) and 4-6% will experience IOP elevations [15 mm Hg (high responders) following 4-6 weeks of topical corticosteroid therapy [14] [15] [16] . These ''steroid responders'' usually have predisposing factors, such as a family history of glaucoma, diabetes mellitus, myopia, or younger age [9, [17] [18] [19] [20] . When this IOP increase persists, patients may develop glaucomatous optic nerve damage and irreversible vision loss [7, 9, 19] .
The exact mechanism of steroid-induced IOP elevation is not fully understood. Genetics clearly play a role in steroid-induced glaucoma.
Studies have shown that corticosteroids can cause multiple physiological changes in the main aqueous humor outflow pathway, the trabecular meshwork. These changes include the formation of cross-linked actin fibers, increased deposition of extracellular matrix material, and inhibition of cell phagocytosis, which together result in an increased resistance to aqueous outflow and thus elevation of IOP [9, 12] . Multiple genes are upregulated in glaucoma, with the most well studied being myocilin which encodes a 55 kDa secreted protein [9] . Mutations in the myocilin gene are linked to both juvenile and adult-onset glaucoma. The protein myocilin is upregulated in trabecular meshwork cells exposed to steroids.
However, the precise mechanism(s) by which myocilin causes glaucoma remains to be elucidated [9] . Loteprednol etabonate (LE) is unique among corticosteroids in that the drug molecule incorporates a metabolically labile moiety which allows rapid metabolism and degradation following glucocorticoid receptor activation, thereby imparting a lower risk of side effects [21] [22] [23] . Unlike other ophthalmic corticosteroids, LE contains a chloromethyl ester instead of a ketone moiety at the carbon 20 (C-20) position of the prednisolone acetate (PA) core structure (Fig. 1) . The metabolically labile C-20 ester group undergoes predictable hydrolysis by endogenous esterases into inactive metabolites (Fig. 1 ). In addition, LE is highly lipophilic and binds the glucocorticoid receptor with 4.3-fold greater affinity than dexamethasone [24] . LE also retains the high potency of prednisolone, with an anti-inflammatory efficacy 20-fold higher than hydrocortisone [22] . [26] , while the other found a clinically significant, yet transient IOP increase in 3% of LE-treated patients [33] . The efficacy and safety of LE 0.5% was compared to that of PA 1% (Pred Forte Ò , Allergan, Irvine, CA, USA) in patients with acute anterior uveitis in two clinical trials [27] . In the first study, medications were administered up to eight times daily initially and continued at a reduced frequency for up to 42 days, while in the second study, medications were administered up to 16 times daily initially and continued at a reduced frequency for up to 28 days. In both studies, the safety profile of LE was more favorable with fewer incidences of IOP increase C10 mm Hg (overall 1/115) than the PA group (overall 7/121). Dell et al. [29, 30] assessed the efficacy and safety of LE 0.5% and 0.2% ophthalmic suspensions administered four times daily in the treatment of seasonal allergic conjunctivitis in two clinical studies conducted over a period of 6 weeks. None of the LE-treated patients in the studies developed a clinically significant IOP elevation, while between 4% and 10% of LE patients had an elevation of C6 mm Hg versus 1-7% of vehicle-treated patients at each study visit with LE 0.5%. In addition, Shulman et al. [32] observed no difference in the incidence of clinically significant IOP elevations between the LE 0.2% (l/67) and vehicle (1/68) groups during 6 weeks of treatment (four times daily regimen) in a randomized, controlled multi-center study of 135 patients with seasonal allergic conjunctivitis. The safety and efficacy of LE 0.5% applied four times daily for 6 weeks in patients with contact lens-related giant papillary conjunctivitis were assessed in two clinical trials [28, 31] . A transient IOP elevation C10 mm Hg was observed in 3% and 7% of LE-treated patients, while there was no IOP elevation in the vehicle-treated groups in the two studies. Using the criterion of C6 mm Hg, 15% and 25% of LE-treated patients compared to 4% and 10% of vehicle-treated patients were observed to have an elevation in IOP in the two studies. Patients were permitted to continue to wear their lenses during these trials, and therefore concomitant use of LE with contact lenses may slightly increase the risk of IOP elevations, as is the case for other corticosteroids. Thus, a presumed depot effect should be considered when prescribing LE to contact lens users or patients using a therapeutic bandage contact lens. Table 2 ). in reducing inflammation after uncomplicated cataract surgery [39, 40] . In an open-label study, Bannale et al. [39] showed similar tolerability and safety profiles of LE 0.5% and flurbiprofen patients [41] . All patients had PA 1% instilled four times daily in the first postoperative week, followed by either PA 1% two times daily for 3 weeks, followed by LE 0.5% twice daily for 1 month and then once daily for 1 month (12 weeks in total), or PA 1% four times daily for three more weeks followed by FML 0.1% three times daily for a month, tapered by one drop per day per month (16 weeks in total). The results showed LE suspension 0.5% and FML 0.1% were both associated with a low incidence of elevated IOP (fewer than three patients at months 2 and 3) when incorporated into treatment protocols for the prevention of post-PRK haze.
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High-Risk Groups
The potential for a corticosteroid to raise IOP is proportional to the duration of treatment [7, 19] . IOP increase is, therefore, a particular concern for patients who require prolonged use of topical corticosteroids. 
Ocular Allergy
A number of studies corroborate data obtained in the pivotal trials indicating that LE suspension 0.2% is safe in the treatment of allergic conjunctivitis. Gong et al. [55] reported that LE 0.2% was comparable to olopatadine 0.1% in efficacy and safety in 300 Chinese patients with seasonal allergic conjunctivitis. In this investigator-masked, parallel-group study, patients were randomized to either LE suspension four times a day or olopatadine an inflammatory eyelid margin disease with secondary conjunctival and corneal involvement. Rhee and Mah [62] reported that neither treatment had a clinically significant effect on mean IOP when administered twice daily for 3-5 days in a controlled single-center study in 40 patients. White and colleagues [63] compared the safety of LE/T and DM/T in 276 patients in a randomized, investigator-masked, parallel-group, multi-center study using the recommended regimen of four times daily for 2 weeks. In contrast to the observation made by Rhee and Mah [62] , White and colleagues [63] found a significant difference between LE/T and DM/T in terms of the mean change from baseline in IOP (-0.1 ± 2.2 vs. 0.6 ± 2.3 mm Hg at day 7, P = 0.03; -0.1 ± 2.4 vs. 1.0 ± 3.0 mm Hg at day 15, P = 0.01 for LE/T and DM/T, respectively). Over the course of the study, 7.1% of the LE/T-treated patients versus 14.4% of the DM/T-treated patients had an increase in IOP of 5-9 mm Hg. One patient in the DM/T group experienced an IOP increase C10 mm Hg. These results are in accord with another randomized comparative multicenter clinical trial of 354 Chinese patients [64] . In this study, patients receiving DM/T had a significantly greater IOP increase from baseline at all follow-up visits as compared to patients receiving LE/T, both dosed four times daily for 2 weeks (P B 0.0186). Patients treated with DM/T also had approximately twice as many IOP elevations as compared to those receiving LE/T of C5 mm Hg (26% vs. 13%, P = 0.0020) and C10 mm Hg (3.4% vs. 7.3%, P = 0.0958). Unlike the study by White et al. [63] , where no patients treated with LE/T had an IOP increase C10 mm Hg, six LE/T-treated patients in the Chinese study experienced a clinically significant IOP increase. This difference was ascribed by the authors to multiple factors including racial diversity and patient age [64] .
The effect of topical corticosteroids on IOP elevation in children is largely unknown. One study suggests that children have a lower rate of ocular hypertensive response to topical corticosteroids [65] , while others have reported a more pronounced steroid-induced IOP effect than in the adult population [66, 67] . The results of two small randomized controlled clinical studies suggest that short-term LE/T therapy is safe in children (aged 0-6 years) with eyelid inflammation or blepharoconjunctivitis [68] . Patients with eyelid inflammation received LE/T four times daily for 7 days followed by twice daily for 7 days; those with blepharoconjunctivitis received LE/T four times daily for 14 days. Mean IOP and IOP changes from baseline, assessed only in the lid inflammation study, were not different between LE/T and vehicle groups at any study visits during 2 weeks of treatment. All study eye IOPs were \30 mm Hg, and all changes from baseline IOP were \10 mm Hg throughout the study.
LE Ointment
LE ointment 0.5% received FDA approval for treatment of postoperative inflammation and pain following ocular surgery based on two randomized, double-masked, parallel-group, vehicle-controlled clinical trials involving a total of more than 800 cataract surgery
patients. An integrated analysis of data from these two studies indicates that mean IOP was consistently lower than baseline over the course of the study in both treatment groups when administered four times daily for 14 days following surgery [69] . The incidence of clinically significant IOP elevation did not differ between the treatment groups (three LE-treated patients and one vehicle-treated patient).
In addition to postoperative management of cataract surgery, LE ointment has been proposed as part of the perioperative regimen for surgical removal of pterygium [70, 71] .
However, no IOP-safety data were identified in the literature for this usage during this review.
LE Gel
The gel formulation of LE 0.5% was approved in 2012 for the treatment of postoperative pain and inflammation following ocular surgery. LE gel 0.5% was well tolerated and had a good safety profile in comparison with vehicle in two identical randomized, controlled clinical studies in patients undergoing cataract surgery [72, 73] . In each study (n = 407 and 406, respectively), patients with anterior chamber inflammation following cataract surgery were randomized to LE gel or vehicle four times daily for two weeks. In both studies, mean IOP decreased over the treatment period in each group, and only one LE-treated patient developed a clinically significant elevation in Three studies evaluated the effect of LE gel 0.5% on IOP over longer-term use. Salinger et al. 
CUMULATIVE IOP ELEVATION INCIDENCE RATES ACROSS PUBLISHED STUDIES
The incidence of IOP elevations from studies which defined clinically significant IOP increase as C10 mm Hg were pooled to provide an aggregate rate of IOP elevation. Of all subjects that received short-term LE treatment, 0.8% (14/1725 subjects) had clinically significant IOP elevations (Table 1 ; Fig. 2 ). With long-term LE treatment, excluding those subjects known to be wearing contact lenses during treatment, the overall incidence of IOP elevation was 1.5% (21/ 1386 subjects)-slightly higher than the 0.6% incidence rate (4/624 subjects) reported by Novack et al. [34] (Table 2 
